© 2022 MJH Life Sciences and Cancer Network. All rights reserved.
© 2022 MJH Life Sciences™ and Cancer Network. All rights reserved.
May 23, 2022
Paul G. Richardson, MD, and Christina Gasparetto, MD, offer insights into the use of proteasome inhibitors in relapsed or refractory multiple myeloma.
April 18, 2022
Experts share their excitement for upcoming PFS trial data to be presented on the combination of ixazomib, pomalidomide, and dexamethasone in multiple myeloma.
April 11, 2022
Expert perspectives on the triplet combination of ixazomib, pomalidomide, and dexamethasone in multiple myeloma presented at the 2021 ASH [American Society of Hematology] Annual Meeting.
Continuing their discussion on the management of multiple myeloma, experts Paul Richardson, MD, and Cristina Gasparetto, MD, consider the value of minimal residual disease as a marker.
April 04, 2022
Insight on the ASH 2021 update highlighting response rates and discontinuation in patients who received in-class transition from bortezomib to ixazomib for multiple myeloma.
Reflections on the patient-reported adherence and outcome data with IRd (ixazomib, lenalidomide, dexamethasone) therapy after an in-class transition from bortezomib to ixazomib for patients with multiple myeloma.
March 28, 2022
Experts Paul Richardson, MD, and Cristina Gasparetto, MD, discuss trial data analyzing the in-class transition from bortezomib to ixazomib for patients with multiple myeloma.
Expert perspectives on data from the TOURMALINE-MM1 trial, which tested ixazomib therapy in patients with relapsed/refractory multiple myeloma.
March 21, 2022
Shared insight on how real-world experience and data with proteasome inhibitors in multiple myeloma compare to what was seen in clinical trials.
A broad look at the historical use of proteasome inhibitor therapy in patients with multiple myeloma centered on 3 agents: bortezomib, carfilzomib, and ixazomib.